Psychedelic medicine reached an important turning point this week. The U.S. Departments of Veterans Affairs and Health and Human Services announced a partnership to accelerate research on psychedelic therapies for military veterans with PTSD, depression, traumatic brain injury, and substance use disorders. At nearly the same time, the FDA finalized its long-awaited guidance for sponsors developing psychedelic medicine, announcing a public hearing on their future therapeutic use. Together with the recent executive order, these actions suggest psychedelic therapies are moving from the scientific margins toward mainstream clinical medicine.